According to the National Institute of Diabetes and Digestive and Kidney Diseases, Pyelonephritis (Kidney Infection) is an infection of the kidney that most often occurs when a urinary tract infection spreads beyond the bladder to the ureters and kidneys.
The most common cause of the disease is a bacterial infection and based on the severity it is classified into acute and chronic pyelonephritis. The main cause of acute pyelonephritis is gram-negative bacteria, the most common being Escherichia coli. Other gram-negative bacteria which cause acute pyelonephritis include Proteus, Klebsiella, and Enterobacter. Acute pyelonephritis can be further subdivided into uncomplicated and complicated pyelonephritis.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/pyelonephritis-market
The Pyelonephritis market report also covers emerging drugs, current treatment practices, Pyelonephritis market share of the individual therapies, current and forecasted Pyelonephritis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Pyelonephritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Pyelonephritis Market Key Facts
-
A population-based study of acute pyelonephritis (APN) in the United States found overall annual rates of 15–17 cases per 10,000 females and 3–4 cases per 10,000 males (Czaja, Scholes, Hooton, & Stamm, 2007).
-
Approximately 20–35% of females experience an episode of APN in their lifetime (Clementi, 2015).
-
An estimated one in 830 people in the UK experience pyelonephritis every year, and females are six times more likely to experience the infection than males.
-
According to a Japanese study, pyelonephritis is one of the causes of end-stage renal disease (ESRD), and among all the major causes of ESRD, age-adjusted incidence rates for men have always been higher than those for women. But the sex ratio was relatively low for pyelonephritis, averaging to be 1.07 (Wakai et al., 2004).
-
The incidence of acute pyelonephritis is highest in healthy women 15 to 29 years of age, followed by infants and older persons (Colgan, Richard & Williams, 2011).
-
According to the study by Czaja et al. (2007), Escherichia coli caused 80% of cases of acute pyelonephritis in women and 70% of cases in men and was less dominant in older age groups.
Key Benefits of Pyelonephritis Market Report
-
Pyelonephritis market report provides an in-depth analysis of Pyelonephritis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Pyelonephritis market report will help in developing business strategies by understanding the Pyelonephritis Market trends & developments, key players, and future market competition that will shape and drive the Pyelonephritis market in the upcoming years.
-
The Pyelonephritis market report covers Pyelonephritis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Pyelonephritis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Pyelonephritis Market size is expected to increase during the study period owing to the expected launch of the therapies. The increasing awareness related to urinary tract infections including pyelonephritis will also boost the pyelonephritis market growth.
The Pyelonephritis market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pyelonephritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Pyelonephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Pyelonephritis Epidemiology
The Pyelonephritis epidemiology section covers insights about the historical and current Pyelonephritis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Pyelonephritis Epidemiology Segmentation –
-
Total Incidence of Pyelonephritis
-
Gender-specific Incidence of Pyelonephritis
-
Incidence of Pyelonephritis by Causative Agents
-
Treatable Cases of Pyelonephritis
Pyelonephritis Drugs Uptake and Key Market Players
The Pyelonephritis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pyelonephritis market or expected to get launched in the market during the study period. The analysis covers Pyelonephritis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pyelonephritis Companies:
Spero Therapeutics
Shionogi
Allecra Therapeutics
VenatoRx Pharmaceuticals
Nabriva Therapeutics
Bayer HealthCare Pharmaceuticals
And many others.
Pyelonephritis Therapies covered in the report include:
Contepo
Tebipenem HBr (SPR994)
Cefepime-Enmetazobactam/AAI101
Cefepime/taniborbactam
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Pyelonephritis Competitive Intelligence Analysis
4. Pyelonephritis Market Overview at a Glance
5. Pyelonephritis Disease Background and Overview
6. Pyelonephritis Patient Journey
7. Pyelonephritis Epidemiology and Patient Population
8. Pyelonephritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Pyelonephritis Unmet Needs
10. Key Endpoints of Pyelonephritis Treatment
11. Pyelonephritis Marketed Products
12. Pyelonephritis Emerging Therapies
13. Pyelonephritis Seven Major Market Analysis
14. Attribute Analysis
15. Pyelonephritis Market Outlook (7 major markets)
16. Pyelonephritis Access and Reimbursement Overview
17. KOL Views on the Pyelonephritis Market.
18. Pyelonephritis Market Drivers
19. Pyelonephritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/pyelonephritis-market
Latest Reports By DelveInsight –
Pyelonephritis Pipeline Insights
Pyelonephritis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pyelonephritis market.
Cardiac Biomarkers Testing Devices Market
DelveInsight’s ‘Cardiac Biomarkers Testing Devices Market Insights, Competitive Landscape and Market Forecast – 2025’ report delivers an in-depth understanding of Cardiac Biomarkers Testing Devices and the historical and forecasted Cardiac Biomarkers Testing Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/